• Profile
Close

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause

Menopause Oct 30, 2018

Labrie F, et al. - Researchers conducted this phase 3 prospective, randomized, double-blind, placebo-controlled study to determine the potential beneficial effects of intravaginal dehydroepiandrosterone (DHEA; prasterone) on moderate to severe dyspareunia or pain at sexual activity—the most frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause (GSM). They examined the effect of daily intravaginal 0.50% DHEA (6.5 mg) on four coprimary objectives: percentage of parabasal cells, percentage or superficial cells, vaginal pH, and moderate to severe pain at sexual activity (dyspareunia). Outcomes revealed that the treatment had clinically and highly statistically significant effects on the four coprimary parameters. The study drug was found to have strictly local action that is in line with the absence of significant drug-related adverse events, indicative of a high benefit-to-risk ratio.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay